Medpace Holdings, Inc. $MEDP Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 285,431 shares of the company’s stock after selling 31,609 shares during the quarter. Bessemer Group Inc.’s holdings in Medpace were worth $137,060,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its stake in Medpace by 164.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock valued at $2,086,000 after purchasing an additional 2,274 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Medpace during the fourth quarter worth about $4,084,000. Cerity Partners LLC grew its holdings in shares of Medpace by 41.0% during the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after buying an additional 23,530 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Medpace by 24,930.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after acquiring an additional 100,968 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Medpace by 881.1% in the 4th quarter. SG Americas Securities LLC now owns 60,144 shares of the company’s stock valued at $33,780,000 after purchasing an additional 54,014 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Up 1.6%

Shares of MEDP opened at $537.92 on Friday. The company has a 50-day simple moving average of $475.82 and a 200-day simple moving average of $494.45. The company has a market capitalization of $15.36 billion, a PE ratio of 33.81, a P/E/G ratio of 2.64 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $306.70 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm’s revenue was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on MEDP shares. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and upped their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Royal Bank Of Canada cut their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Robert W. Baird restated a “neutral” rating and issued a $547.00 target price (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Finally, Mizuho raised their price objective on shares of Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a research report on Monday. Two equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $469.50.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.